An FDA advisory committee has voted by a huge margin that BrainStorm’s stem cell therapy for amyotrophic lateral sclerosis (ALS) – NurOwn – does not have enough data to su
Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug tar
Sano Genetics has been awarded a grant from Innovate UK to explore the psychological impact on people at risk of motor neurone disease (MND) – also known as amyotrophic la
The litany of failed experimental therapies for amyotrophic lateral sclerosis (ALS) added another verse today, after Apellis Pharma gave up on Sobi-partnered candidate peg
After much deliberation, the FDA has granted accelerated approval for Biogen’s tofersen for an ultra-rare form of the neurodegenerative disease amyotrophic lateral scleros
There’s been a big disappointment for people with amyotrophic lateral sclerosis (ALS), after Cytokinetics said it was halting a trial of its resedemtiv candidate following
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh